概要
The GH Max Stack represents the most aggressive non-exogenous approach to maximizing growth hormone output, combining three distinct mechanisms of GH stimulation. CJC-1295 with DAC (Drug Affinity Complex) is a modified GHRH analog conjugated to a protein that extends its half-life to approximately 8 days. Unlike the no-DAC version, it provides a sustained elevation of baseline GH levels rather than discrete pulses, creating a continuously elevated "floor" of GH secretion throughout the week. MK-677 (Ibutamoren) is an orally active, non-peptide ghrelin receptor agonist with a 24-hour half-life. It provides continuous GHS-R1a activation, complementing the sustained GHRH signaling from CJC-1295 with DAC. Clinical trials have demonstrated MK-677 increases IGF-1 levels by 40-60% in elderly subjects and improves nitrogen balance — a surrogate for anabolic activity. Daily Ipamorelin injections add targeted GH pulses on top of the elevated baseline, creating both sustained elevation and superimposed pulsatile peaks. This triple-mechanism approach produces GH and IGF-1 levels that approach or exceed physiological youth ranges. However, the advanced classification reflects significant considerations: MK-677 substantially increases appetite (via ghrelin pathway activation), may raise fasting blood glucose and HbA1c over time, and can cause water retention. The sustained GH elevation from CJC-1295 with DAC means less receptor recovery time compared to pulsatile protocols. This stack requires regular monitoring of fasting glucose, IGF-1 levels, and ideally HbA1c every 3 months. It is contraindicated in individuals with diabetes, pre-diabetes, active malignancy, or family history of pituitary tumors.
投与プロトコル
2,000 mcg
1回の投与あたり
300 mcg
1回の投与あたり
25,000 mcg
1回の投与あたり
目標と証拠
警告
- MK-677 increases appetite significantly and may raise blood glucose. Not suitable for diabetics or pre-diabetics. CJC-1295/Ipamorelin remain FDA Category 2 (restricted) as of July 2026.
Comments
Sign in to join the discussion
注意: このスタックはコミュニティから提出され、研究用のみです。Peptide Contactsは提出されたスタックの安全性や効果性を確認していません。使用するペプチドプロトコル前に常に資格のある医療専門家に相談してください。